Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 3 results

ea0099p116 | Pituitary and Neuroendocrinology | ECE2024

Cell lineage specific differences in clinical behavior of clinically non-functioning pituitary adenomas according to the 2017 WHO classification – a systematic review and meta-analysis

van der Hoeven Loren , Slagboom Tessa , Malekzadeh Arjan , Hoogmoed Jantien , Drent Madeleine , Aronica Eleonora , Jan Stenvers Dirk , Pereira Alberto

Background: In 2017, the World Health Organization (WHO) adjusted the histopathological classification of pituitary adenomas (PAs) by including pituitary cell lineage specific transcription factors (TFs), elucidating a continuous spectrum between true null cell (NCA), silent, clinically silent, and functioning adenomas. The definitions of non-functioning (silent) gonadotroph, corticotroph, somatolactotroph and thyrotroph adenomas were previously reserved for immunohistochemica...
0 shares

ea0070ep340 | Pituitary and Neuroendocrinology | ECE2020

The galant trial: a randomised placebo-controlled trial in patients with a gallium-68 dotatate pet positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size

Boertien Tessel M. , Drent M.L. , Booij Jan , Majoie Charles B.L.M. , Stokkel Marcel P.M. , Hoogmoed Jantien , Pereira Alberto M , Biermasz Nienke , Simsek Suat , Veldman Ronald Groote , Tanck Michael W.T. , Fliers Eric , Bisschop Peter H.

Rationale: At present, there is no approved medical treatment for patients with clinically non-functioning pituitary adenoma. A number of open-label studies suggest that treatment with somatostatin analogues may prevent tumour progression in selected patients. In vivo assessment of somatostatin receptor status using 68Ga-DOTATATE PET could help to select patients responsive to treatment.Trial objective: To investigate the effect of the somatosta...
0 shares

ea0099rc5.2 | Rapid Communications 5: Pituitary and Neuroendocrinology | Part I | ECE2024

Lanreotide in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): A randomised, double-blind, placebo-controlled trial

Boertien Tessel M. , Drent M.L. , Booij Jan , Majoie Charles B.L.M. , Stokkel Marcel P.M. , Hoogmoed Jantien , Pereira Alberto M. , Biermasz Nienke , Simsek Suat , Groote Veldman Ronald , Weterings Annick J. , Vink Juan M. , Tanck Michael W.T. . , Fliers Eric , Bisschop Peter H.

Background: Patients with non-functioning pituitary macroadenoma (NFMA) currently have no established medical treatment options. Somatostatin analogues may decrease tumour size, but randomised controlled trials are lacking. In vivo somatostatin receptor assessment with 68Ga-DOTATATE PET could help in selecting patients for treatment. We aimed to determine the effect of the somatostatin analogue lanreotide on tumour size in patients with a 68Ga-DOTATATE PE...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more